Patents by Inventor Jose Sebastian Franzone

Jose Sebastian Franzone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of non-steroidal anti-inflammatory drugs by inhalation in the treatment of acute and chronic bronchitis
    Patent number: 9132109
    Abstract: A method for treating non-asthmatic bronchitis with a particular lysine acetylsalicylate is described. The lysine acetylsalicylate is delivered by nebulizer, preferably, to treat acute bronchitis, chronic bronchitis, emphysema and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 15, 2015
    Assignee: MEDESTEA RESEARCH & PRODUCTION S.P.A.
    Inventors: Jose Sebastian Franzone, Sebastiano Bianco, Giuseppe Zuccari, Claudio Franco Omini
  • PROCESS FOR THE PREPARATION OF STEM CELLS FROM HUMAN MUSCLE TISSUE AND ADIPOSE TISSUE, AND STEM CELLS OBTAINABLE BY THIS PROCESS
    Publication number: 20100158876
    Abstract: The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process.
    Type: Application
    Filed: October 28, 2009
    Publication date: June 24, 2010
    Inventors: Giulio ALESSANDRI, Arnaldo Caruso, Josè Sebastian Franzone
  • Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein
    Patent number: 7541036
    Abstract: New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1 is an amino acid residue selected from Ser and Arg; X2 is an amino acid residue selected from Gly, Glu and Ser; X3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X5 is an amino acid residue selected from Lys, Arg and Ser; and X6 is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: June 2, 2009
    Assignee: Medestea Internazionale S.r.l.
    Inventors: Arnaldo Caruso, Jose Sebastian Franzone
  • Use of Non-Steroidal Anti-Inflammatory Drugs by Inhalation in the Treatment of Acute and Chronic Bronchitis
    Publication number: 20080306033
    Abstract: This invention claims the use of non-steroidal anti-inflammatory drugs, and in particular lysine acetylsalicylate, delivered by nebuliser, to treat non-asthmatic bronchitis, namely acute bronchitis, chronic bronchitis, emphysema and chronic obstructive pulmonary disease.
    Type: Application
    Filed: March 10, 2006
    Publication date: December 11, 2008
    Applicant: MEDESTA RESEARCH & PRODUCTION S.P.A.
    Inventors: Jose Sebastian Franzone, Sebastiano Bianco, Giuseppe Zuccari, Claudio Franco Omini
  • Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope
    Publication number: 20040249124
    Abstract: New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1 is an amino acid residue selected from Ser and Arg; X2 is an amino acid residue selected from Gly, Glu and Ser; X3 is an amino acid residue selected from Glu, Lys, Asp and Arg; X4 is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X5 is an amino acid residue selected from Lys, Arg and Ser; and X6 is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
    Type: Application
    Filed: July 30, 2004
    Publication date: December 9, 2004
    Inventors: Arnaldo Caruso, Jose Sebastian Franzone